Price Drives Cardiac Growth in India's Top 10 Pharma Therapies

Among the leading 10 therapies that account for over 90% of the Indian pharmaceutical market, price was the key factor in the expansion of the cardiac sector. The anti-hypertensive medications, comprising nearly 50% of the cardiac sector, are facing flat volume growth. Lipid-lowering medications and platelet aggregation inhibitors have demonstrated a relatively greater increase to enhance the cardiac sector.

In the anti-infective category, antibacterials, accounting for nearly 87%, have reduced the volumes. In contrast, antifungals have increased in quantity.

Antacids, making up nearly 40% of the gastro category, have experienced a decline in sales volume, while laxatives, probiotics, anti-infectives, and anti-diarrheal products have demonstrated volume increases. "These are the factors that have increased the volume growth, while the antacids are responsible for reducing the segment's growth," Sapale stated.

In the anti-diabetes sector, the combinations of oral anti-diabetics have evidenced a decline in volume growth, whereas significant growth is attributed to new product launches, as numerous items have expired patents, according to Pharmarack data.

Vitamins and nutraceuticals, which together account for 70% of the nutrition market, have experienced a decline in volumes, leading to a slowdown in growth for this segment. Calcium products and others also experienced a decline, but their impact on the nutritionist category is smaller.